NASDAQ:ABMD - ABIOMED Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$427.29 -10.98 (-2.51 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$427.29
Today's Range$426.99 - $444.07
52-Week Range$139.49 - $450.93
Volume1.04 million shs
Average Volume1.36 million shs
Market Capitalization$19.49 billion
P/E Ratio174.40
Dividend YieldN/A
Beta0.21
ABIOMED logoABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio5.84
Quick Ratio5.24

Price-To-Earnings

Trailing P/E Ratio174.40
Forward P/E Ratio122.08
P/E Growth4.64

Sales & Book Value

Annual Sales$593.75 million
Price / Sales32.01
Cash Flow$2.7121 per share
Price / Cash157.55
Book Value$15.57 per share
Price / Book27.44

Profitability

EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins18.89%
Return on Equity17.58%
Return on Assets15.37%

Miscellaneous

Employees1,143
Outstanding Shares44,480,000

The Truth About Cryptocurrencies

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Thursday, May, 3rd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.16. The medical equipment provider earned $174.44 million during the quarter, compared to analysts' expectations of $164.30 million. ABIOMED had a net margin of 18.89% and a return on equity of 17.58%. The company's revenue for the quarter was up 39.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.33 earnings per share. View ABIOMED's Earnings History.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for ABIOMED.

What price target have analysts set for ABMD?

8 brokers have issued 12 month target prices for ABIOMED's shares. Their predictions range from $280.00 to $480.00. On average, they anticipate ABIOMED's stock price to reach $363.1429 in the next twelve months. View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, Chief Exec. Officer and Pres (Age 51)
  • Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
  • Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
  • Mr. Todd A. Trapp, CFO & VP (Age 47)

Has ABIOMED been receiving favorable news coverage?

Media headlines about ABMD stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ABIOMED earned a media sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.35%), Baillie Gifford & Co. (4.62%), Palo Alto Investors LP (3.04%), Winslow Capital Management LLC (1.77%), American Century Companies Inc. (1.75%) and Franklin Resources Inc. (1.41%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Which major investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Millennium Management LLC, American Century Companies Inc., Wells Fargo & Company MN, Sei Investments Co., Scout Investments Inc., Blair William & Co. IL and OppenheimerFunds Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Paul Thomas and William J Bolt. View Insider Buying and Selling for ABIOMED.

Which major investors are buying ABIOMED stock?

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Franklin Resources Inc., BlackRock Inc., JPMorgan Chase & Co., Rockefeller Capital Management L.P., Prudential Financial Inc., Baillie Gifford & Co. and FIL Ltd. View Insider Buying and Selling for ABIOMED.

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $427.29.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $19.49 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (ABMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  601
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.